There are many factors to consider when looking at the most effective treatment methods for multiple sclerosis. A new area researchers are looking at is ways to prevent brain volume loss beyond what most people experience over the course of their lives.
In six years since fingolimod was approved for the treatment of relapsing remitting multiple sclerosis a considerable amount of data has been collected about the oral medication.
There have been great strides made in recent years to help treat patients diagnosed with heart disease. As technology improves and new medications are developed it will be important to ensure they can get to the patients who need them most.
As Zika cases mount, US funds a second vaccine project. Sanofi Pasteur and Walter Reed Army Research are getting $43.18 million. There are now at least 749 pregnant women in the US States with known Zika infections.
While lifestyle modifications and changes in diet can help prevent heart disease in men and women alike there are some distinct differences when it comes to treating these patients once a diagnosis is made.
As more has been learned over the years about heart disease there is also a greater awareness of the impact it can have on women. Because of this increased awareness a greater effort is underway to help catch these conditions before they become fatal.
A graft consisting of a monolayer sheet of RPE or a complex graft of RPE and Bruch’s membrane were found equally effective in restoring visual function and central fixation stability.
The drug, a fully human monoclonal antibody that has impressed equally in asthma and atopic dermatitis trials, may be approved for market as soon as March of 2017.
In the field of neurosurgery it can seem like each new day is the future. Even still there are goals to achieve that may not be reached until many years down the road.